Efficacy of Dexmedetomidine As an Adjuvant to Bupivacaine in Pericapsular Nerve Group Block in Hip Replacement Surgeries

ConditionPENG Block
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-90
SponsorAssiut University

About this trial

Our aim will be to investigate the efficacy of dexmedetomidine as an adjuvant to bupivacaine in ultrasound guided pericapsular nerve group (PENG) block for postoperative analgesia in hip replacement surgeries.

* Our primary outcome of the study: total amount of postoperative morphine consumption in the first 24h postoperative. * Our secondary outcome of the study: postoperative analgesia assessed by pain score (by Visual Analog Scale)

Eligibility criteria

Qualifiers

Patients aged from 18 years to 90 years

Gender : both males and females

BMI less than 35 kg/m2

Patients with American society of anesthesiologists (ASA) classification class I , II or III

Disqualifiers

Patient declining to give written informed consent

Patient with infection at the site of injection

Patient with coagulopathy

Patients with known allergy to used medications.

Trial design

Treatments tested in this trial

  • Ultrasound guided Pericapsular Nerve Group Block
  • Isobaric Bupivacaine 0. 25%
  • 20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine
  • the ultrasound machine with curvilinear transducer (high -frequency probe, 2.5Mhz to 7.5Mhz)
  • a standard echogenic 20-22 gauge 100mm needle

Treatment groups

60 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators